JP2005525371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525371A5 JP2005525371A5 JP2003574134A JP2003574134A JP2005525371A5 JP 2005525371 A5 JP2005525371 A5 JP 2005525371A5 JP 2003574134 A JP2003574134 A JP 2003574134A JP 2003574134 A JP2003574134 A JP 2003574134A JP 2005525371 A5 JP2005525371 A5 JP 2005525371A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- compound
- amino
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 nitro, hydroxyl Chemical group 0.000 claims 111
- 150000001875 compounds Chemical class 0.000 claims 69
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000004432 carbon atom Chemical group C* 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 125000002252 acyl group Chemical group 0.000 claims 23
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 23
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 125000004423 acyloxy group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000004438 haloalkoxy group Chemical group 0.000 claims 15
- 125000004001 thioalkyl group Chemical group 0.000 claims 15
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 8
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 8
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000000962 organic group Chemical group 0.000 claims 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 230000037356 lipid metabolism Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- GXJFKJQSRGQZGR-UHFFFAOYSA-N 2-[[7-[5-ethenyl-2-(trifluoromethoxy)phenyl]-3,3-dimethyl-2h-1-benzofuran-5-yl]methoxy]ethanol Chemical compound CC1(C)COC2=C1C=C(COCCO)C=C2C1=CC(C=C)=CC=C1OC(F)(F)F GXJFKJQSRGQZGR-UHFFFAOYSA-N 0.000 claims 1
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical group O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 claims 1
- WYPANKNORPQJBO-UHFFFAOYSA-N 5-[[3-(3,3-dimethyl-5-methylsulfonyl-2h-1-benzofuran-7-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1(C)COC2=C1C=C(S(C)(=O)=O)C=C2C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O WYPANKNORPQJBO-UHFFFAOYSA-N 0.000 claims 1
- GOYKDWCTWAKXSY-UHFFFAOYSA-N 5-[[3-(5-acetyl-3,3-dimethyl-2h-1-benzofuran-7-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C(C(=O)C)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O GOYKDWCTWAKXSY-UHFFFAOYSA-N 0.000 claims 1
- ZJCNMAXBWOCKCH-UHFFFAOYSA-N 5-[[3-[3,3-dimethyl-5-(1,2-oxazol-5-yl)-2h-1-benzofuran-7-yl]-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1(C)COC2=C1C=C(C=1ON=CC=1)C=C2C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O ZJCNMAXBWOCKCH-UHFFFAOYSA-N 0.000 claims 1
- IIABODSWSJVMPL-UHFFFAOYSA-N 5-[[3-[3,3-dimethyl-5-(1,3-oxazol-2-yl)-2h-1-benzofuran-7-yl]-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1(C)COC2=C1C=C(C=1OC=CN=1)C=C2C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O IIABODSWSJVMPL-UHFFFAOYSA-N 0.000 claims 1
- RHAXOVIBEIBLCS-UHFFFAOYSA-N 5-[[3-[3,3-dimethyl-5-(2-methylpropyl)-2h-1-benzofuran-7-yl]-2,5-difluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound FC1=C(C=2C3=C(C(CO3)(C)C)C=C(CC(C)C)C=2)C(OC)=C(F)C=C1C=C1SC(=O)NC1=O RHAXOVIBEIBLCS-UHFFFAOYSA-N 0.000 claims 1
- HPZMJNWGVDLITO-UHFFFAOYSA-N 5-[[3-[3,3-dimethyl-5-(2-methylpropyl)-2h-1-benzofuran-7-yl]-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C(CC(C)C)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O HPZMJNWGVDLITO-UHFFFAOYSA-N 0.000 claims 1
- JDCHZNVEEADSFN-UHFFFAOYSA-N 5-[[3-[5-(furan-3-yl)-3,3-dimethyl-2h-1-benzofuran-7-yl]-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1(C)COC2=C1C=C(C1=COC=C1)C=C2C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O JDCHZNVEEADSFN-UHFFFAOYSA-N 0.000 claims 1
- BUCSWOOTHTYFNE-UHFFFAOYSA-N 5-[[3-[5-(methoxymethyl)-3,3-dimethyl-2h-1-benzofuran-7-yl]-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C(COC)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O BUCSWOOTHTYFNE-UHFFFAOYSA-N 0.000 claims 1
- KMVZOYWRGKZLGB-UHFFFAOYSA-N 5-[[3-[6-(2-methylpropyl)-1,3-benzodioxol-4-yl]-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C=1C(CC(C)C)=CC=2OCOC=2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O KMVZOYWRGKZLGB-UHFFFAOYSA-N 0.000 claims 1
- GZGJZTKREUNCGV-UHFFFAOYSA-N 7-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-(trifluoromethoxy)phenyl]-3,3-dimethyl-2h-1-benzofuran-5-carboxylic acid Chemical compound CC1(C)COC2=C1C=C(C(O)=O)C=C2C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O GZGJZTKREUNCGV-UHFFFAOYSA-N 0.000 claims 1
- UTAGEPVUNHXEAG-UHFFFAOYSA-N 7-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-(trifluoromethoxy)phenyl]-n,3,3-trimethyl-2h-1-benzofuran-5-carboxamide Chemical compound C=1C(C(=O)NC)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O UTAGEPVUNHXEAG-UHFFFAOYSA-N 0.000 claims 1
- BEMFENZSTXJOCT-UHFFFAOYSA-N 7-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-(trifluoromethoxy)phenyl]-n,3,3-trimethyl-2h-1-benzofuran-5-sulfonamide Chemical compound C=1C(S(=O)(=O)NC)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O BEMFENZSTXJOCT-UHFFFAOYSA-N 0.000 claims 1
- BOLNQUPXEJLMMP-UHFFFAOYSA-N 7-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-(trifluoromethoxy)phenyl]-n,n,3,3-tetramethyl-2h-1-benzofuran-5-carboxamide Chemical compound C=1C(C(=O)N(C)C)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O BOLNQUPXEJLMMP-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000005332 alkyl sulfoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- UCFNUNDTGDWNKC-UHFFFAOYSA-N methyl 7-[5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-(trifluoromethoxy)phenyl]-3,3-dimethyl-2h-1-benzofuran-5-carboxylate Chemical compound C=1C(C(=O)OC)=CC(C(CO2)(C)C)=C2C=1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O UCFNUNDTGDWNKC-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 claims 1
- 0 C**c1c2OC(*C)(*3(C)*=C3)C(C)(*C)c2cc(*)c1 Chemical compound C**c1c2OC(*C)(*3(C)*=C3)C(C)(*C)c2cc(*)c1 0.000 description 5
- GXITUSCERRRNDI-UHFFFAOYSA-N C=C(C(N1)=O)SC1=O Chemical compound C=C(C(N1)=O)SC1=O GXITUSCERRRNDI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36273202P | 2002-03-08 | 2002-03-08 | |
| PCT/US2003/007240 WO2003075858A2 (en) | 2002-03-08 | 2003-03-07 | Bicyclic heterocycles for the treatment of diabetes and other diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525371A JP2005525371A (ja) | 2005-08-25 |
| JP2005525371A5 true JP2005525371A5 (https=) | 2006-03-23 |
Family
ID=27805219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574134A Pending JP2005525371A (ja) | 2002-03-08 | 2003-03-07 | 糖尿病および他の疾患を治療するための二環式複素環 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7196108B2 (https=) |
| EP (1) | EP1487446A4 (https=) |
| JP (1) | JP2005525371A (https=) |
| AU (1) | AU2003223233A1 (https=) |
| BR (1) | BR0308278A (https=) |
| CA (1) | CA2478765A1 (https=) |
| IL (1) | IL163953A0 (https=) |
| TW (1) | TWI277415B (https=) |
| WO (1) | WO2003075858A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508391A (ja) | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| AU2002252227A1 (en) * | 2001-03-07 | 2002-09-24 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| WO2003016267A1 (en) * | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| WO2004001385A2 (en) * | 2002-06-25 | 2003-12-31 | Helicon Therapeutics, Inc. | Altering memory by affecting staufen function |
| KR100897642B1 (ko) | 2002-12-20 | 2009-05-14 | 글락소 그룹 리미티드 | 신경 장애 치료용 벤즈아제핀 유도체 |
| US20050038098A1 (en) * | 2003-04-18 | 2005-02-17 | Catherine Tachdjian | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| WO2006116165A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Chromane and chromene derivatives and uses thereof |
| EP1937641A2 (en) * | 2005-09-30 | 2008-07-02 | Janssen Pharmaceutica, N.V. | Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| BRPI1010974A2 (pt) | 2009-05-22 | 2019-09-24 | Exelixis Inc | benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas |
| CN102459248A (zh) | 2009-05-26 | 2012-05-16 | 埃克塞里艾克西斯公司 | 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法 |
| ES2642586T3 (es) | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| CA2809847A1 (en) * | 2010-09-01 | 2012-03-08 | The Regents Of The University Of California | Cell culture screen for agents that control adipogenesis and myofibroblast differentiation |
| US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| WO2014082042A2 (en) | 2012-11-25 | 2014-05-30 | The Regents Of The University Of California | Peptides that stimulate subcutaneous adipogenesis |
| WO2015184125A1 (en) | 2014-05-28 | 2015-12-03 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| JPS5538359A (en) | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
| US4971996A (en) | 1987-03-11 | 1990-11-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors |
| US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| IE62214B1 (en) | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| EP0595868B1 (en) | 1991-07-22 | 1998-11-25 | Pfizer Inc. | Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene |
| US5780676A (en) | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| ATE195716T1 (de) | 1992-04-22 | 2000-09-15 | Ligand Pharm Inc | Retinoid-x rezeptor selektive verbindungen |
| NZ248573A (en) | 1992-09-10 | 1996-02-27 | Lilly Co Eli | 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions |
| EP0671005A1 (en) | 1992-11-25 | 1995-09-13 | La Jolla Cancer Research Foundation | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
| EP0745063B1 (en) | 1994-02-17 | 1999-03-24 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
| US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
| US5520752A (en) * | 1994-06-20 | 1996-05-28 | The United States Of America As Represented By The Secretary Of The Army | Composite solders |
| JPH09136877A (ja) | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | 複素環化合物、その製造法及び用途 |
| EP0850067A4 (en) | 1995-07-17 | 1999-12-15 | Cird Galderma | METHODS OF TREATING CANCER USING 6- 3- 1-ADAMANTYL] -4-HYDROXYPHENYL] |
| JP2000511875A (ja) | 1996-06-19 | 2000-09-12 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病活性を増強されたトログリタゾンの新規な多形型及びそれらの製造方法 |
| TR199900684T2 (xx) | 1996-07-08 | 1999-07-21 | Galderma Research & Development, S.N.C. | Apoptoz uyar�c� adamantil t�revleri ve bunlar�n kansere kar�� maddeler olarak kullan�m�. |
| AU8747998A (en) | 1997-08-21 | 1999-03-16 | Takeda Chemical Industries Ltd. | Anti-inflammatory agent |
| WO1999024415A1 (en) | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
| US6235996B1 (en) * | 1998-01-28 | 2001-05-22 | International Business Machines Corporation | Interconnection structure and process module assembly and rework |
| US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| WO2001036402A1 (en) | 1998-07-14 | 2001-05-25 | Fujimoto Brothers Co., Ltd. | Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
| WO2000010573A1 (en) | 1998-08-21 | 2000-03-02 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
| WO2000018748A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000032598A1 (en) | 1998-12-04 | 2000-06-08 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| JP2003508391A (ja) | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用 |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| AU2002252227A1 (en) | 2001-03-07 | 2002-09-24 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| JP2004523571A (ja) | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| DE60204674T2 (de) | 2001-03-14 | 2006-05-18 | Eli Lilly And Co., Indianapolis | Retinoid x rezeptormodulatoren |
| WO2002080935A1 (en) | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| WO2003016267A1 (en) | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 |
| AR037714A1 (es) | 2001-12-06 | 2004-12-01 | Maxia Pharmaceuticals Inc | Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US20050014767A1 (en) | 2003-01-29 | 2005-01-20 | Magnus Pfahl | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
| US20050038098A1 (en) | 2003-04-18 | 2005-02-17 | Catherine Tachdjian | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
-
2003
- 2003-03-06 US US10/384,391 patent/US7196108B2/en not_active Expired - Fee Related
- 2003-03-07 JP JP2003574134A patent/JP2005525371A/ja active Pending
- 2003-03-07 IL IL16395303A patent/IL163953A0/xx unknown
- 2003-03-07 BR BR0308278-4A patent/BR0308278A/pt not_active IP Right Cessation
- 2003-03-07 EP EP03719363A patent/EP1487446A4/en not_active Withdrawn
- 2003-03-07 WO PCT/US2003/007240 patent/WO2003075858A2/en not_active Ceased
- 2003-03-07 CA CA002478765A patent/CA2478765A1/en not_active Abandoned
- 2003-03-07 AU AU2003223233A patent/AU2003223233A1/en not_active Abandoned
- 2003-03-07 TW TW092105026A patent/TWI277415B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525371A5 (https=) | ||
| KR101179087B1 (ko) | 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법 | |
| US8268867B2 (en) | 1,3-dioxane carboxylic acids | |
| AU754488B2 (en) | Method for treating diabetes employing an aP2 inhibitor and combination | |
| JP2007523905A5 (https=) | ||
| US5599826A (en) | Thiazolidinediones and drugs containing them | |
| JP2005530705A5 (https=) | ||
| JP2009542659A5 (https=) | ||
| JPH10194970A (ja) | 置換チアゾリジンジオン誘導体を含む抗高脂血剤 | |
| CN1131391A (zh) | 噻唑烷二酮衍生物及相关的抗高血糖药物在治疗患有非胰岛素依赖性糖尿病危险病症中的应用 | |
| MX2009000290A (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso. | |
| RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
| KR20080034436A (ko) | 암 치료에 사용되는 티아졸 유도체 및 유사체 | |
| JP2005526732A5 (https=) | ||
| RU2004129752A (ru) | Гетероциклические амидные промзводные для лечения диабета и других заболеваний | |
| JP2013507397A5 (https=) | ||
| US7144906B2 (en) | Heterocyclic compounds | |
| RU2006138485A (ru) | 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение | |
| JP2008214305A (ja) | 置換アミン誘導体及びこれを有効成分とする医薬組成物 | |
| JP2013500961A (ja) | グルコキナーゼ（ｇｋ）アクチベーターとしての置換ベンズアミド誘導体 | |
| RU2435763C2 (ru) | Ингибиторы тирозинфосфатазы белка человека и способы применения | |
| RU2005141516A (ru) | Производные анилина | |
| JP3893166B2 (ja) | ベンゾフラン誘導体およびそれを含んでなる医薬組成物 | |
| RU2006102866A (ru) | Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar | |
| MX2008008670A (en) | 1,3-dioxane carboxylic acids |